Payment overview · 2025
General Payments
$14.63
1 reported records · 1 companies
Healthcare provider profile · identity verified
Vikil Kumar Girdhar, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · AKRON, OH · NPI 1740535277
Verified facts
What the public records show
CMS Open Payments records show Vikil Kumar Girdhar, M.D. received $14.63 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.63 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $14.63 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 455 | 117 |
| Lisinopril | Lisinopril | 395 | 88 |
| Gabapentin | Gabapentin | 330 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 270 | 78 |
| Omeprazole | Omeprazole | 198 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 184 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 172 | 37 |
| Furosemide | Furosemide | 169 | 25 |
| Losartan Potassium | Losartan Potassium | 156 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 35 |
| Metformin Hcl | Metformin Hcl | 153 | 41 |
| Trazodone Hcl | Trazodone Hcl | 152 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 124 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 32 |
| Metformin Hcl Er | Metformin Hcl | 116 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 105 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 100 | 14 |
| Buspirone Hcl | Buspirone Hcl | 92 | 19 |
| Spironolactone | Spironolactone | 92 | suppressed |
| Ibuprofen | Ibuprofen | 88 | 23 |
| Bupropion Xl | Bupropion Hcl | 84 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 17 |
| Meloxicam | Meloxicam | 65 | 14 |
| Carvedilol | Carvedilol | 64 | 17 |
| Sertraline Hcl | Sertraline Hcl | 64 | 16 |
| Lamotrigine | Lamotrigine | 61 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 16 |
| Propranolol Hcl | Propranolol Hcl | 59 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 57 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 11 |
| Oxcarbazepine | Oxcarbazepine | 53 | suppressed |
| Glipizide | Glipizide | 52 | 16 |
| Midodrine Hcl | Midodrine Hcl | 52 | suppressed |
| Chlorthalidone | Chlorthalidone | 51 | 23 |
| Naproxen | Naproxen | 51 | 17 |
| Lorazepam | Lorazepam | 49 | 16 |
| Eliquis | Apixaban | 48 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | suppressed |
| Potassium Chloride | Potassium Chloride | 47 | 11 |
| Fenofibrate | Fenofibrate | 46 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 44 | 14 |
| Famotidine | Famotidine | 41 | 15 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 33 | suppressed |
| Mirtazapine | Mirtazapine | 32 | 11 |
| Tramadol Hcl | Tramadol Hcl | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Simvastatin | Simvastatin | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 21 |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Allopurinol | Allopurinol | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Abilify Maintena | Aripiprazole | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14.63 · 1 records | ABBVIE INC. | VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error